Race Oncology Limited
Race Oncology Limited (RAC.AX) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Race Oncology Limited (RAC.AX), featuring income statements, balance sheets, and cash flow data.
Race Oncology Limited (RAC.AX) Income Statement & Financial Overview
Review Race Oncology Limited RAC.AX income statement with detailed quarterly and annual figures.
| Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
|---|---|---|---|---|
| Revenue | $5.25M | $0.00 | $4.003M | $1.81M |
| Cost of Revenue | $379673.00 | $769426.00 | $140598.00 | $140598.00 |
| Gross Profit | $4.88M | -$769000.00 | $3.86M | $1.67M |
| Gross Profit Ratio | $0.93 | $0.00 | $0.97 | $0.92 |
| R&D Expenses | $2.44M | $4.87M | $6.11M | $4.43M |
| SG&A Expenses | $1.66M | $2.32M | $3.37M | $2.85M |
| Operating Expenses | $4.10M | $7.20M | $9.47M | $7.28M |
| Total Costs & Expenses | $4.48M | $7.96M | $9.61M | $7.42M |
| Interest Income | $0.00 | $371149.00 | $461428.00 | $424155.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $140598.00 | $140598.00 | $140598.00 | $140598.00 |
| EBITDA | $328747.00 | -$8.02M | -$9.53M | -$7.18M |
| EBITDA Ratio | $0.06 | $0.00 | -$2.38 | -$4.02 |
| Operating Income | $778602.00 | -$7.96M | -$9.61M | -$7.42M |
| Operating Income Ratio | $0.15 | $0.00 | -$2.40 | -$4.09 |
| Other Income/Expenses (Net) | -$276000.00 | -$192000.00 | -$4.25M | $93725.00 |
| Income Before Tax | $502163.00 | -$8.16M | -$9.67M | -$7.32M |
| Income Before Tax Ratio | $0.10 | $0.00 | -$2.41 | -$4.04 |
| Income Tax Expense | $0.00 | $0.00 | -$4.003M | -$1.81M |
| Net Income | $502163.00 | -$8.16M | -$5.66M | -$5.51M |
| Net Income Ratio | $0.10 | $0.00 | -$1.41 | -$3.04 |
| EPS | $0.003 | -$0.05 | -$0.03 | -$0.03 |
| Diluted EPS | $0.003 | -$0.05 | -$0.03 | -$0.03 |
| Weighted Avg Shares Outstanding | $193.14M | $165.33M | $163.50M | $163.07M |
| Weighted Avg Shares Outstanding (Diluted) | $193.14M | $165.33M | $163.50M | $163.07M |
Over the past four quarters, Race Oncology Limited demonstrated steady revenue growth, increasing from $1.81M in Q4 2023 to $5.25M in Q2 2025. Operating income reached $778602.00 in Q2 2025, maintaining a consistent 15% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $328747.00, reflecting operational efficiency. Net income rose to $502163.00, with EPS at $0.003. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan